Generated by AI
Tango Therapeutics Inc. is a biotechnology company focused on discovering and developing precision oncology therapies. The company applies synthetic lethality and target discovery approaches to identify cancer dependencies that can be addressed with medicines designed for specific tumor types. Its current pipeline centers on programs in oncology, including PRMT5 inhibitor candidates aimed at cancers such as pancreatic, lung, and brain tumors, along with research efforts tied to tumor suppressor gene loss and other genetically defined patient populations. Tango Therapeutics Inc. operates in the clinical-stage drug development segment, where its work contributes to the broader precision medicine market by advancing targeted approaches intended to improve cancer treatment specificity. The company is headquartered in Boston, Massachusetts, and is positioned within the life sciences sector as a developer of innovative therapeutic candidates for patients with high unmet medical need.
Website201 Brookline Avenue
Boston, MA, 02215
United States
The latest articles about TNGX.
Tango Therapeutics reported a third quarter 2026 net loss of US$68.39 million and a nine month loss of US$169.25 million, while moving its precision oncology pipeline forward. The new Phase 1/2 combination trial of vopimetostat with ERAS-0015 in MTAP-deleted pancreatic and lung cancers deepens Tango Therapeutics' focus on MTAP-driven tumor biology despite higher recent losses. We will now look at how Tango Therapeutics' investment narrative is affected by deeper vopimetostat combinations...
Summary of Oct 24's posts. Generated by AI.
Summary of Oct 23's posts. Generated by AI.
Summary of Oct 23's posts. Generated by AI.
Investors talking about TNGX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.